Moreover, downregulation of RPS19 or RPL39 suppressed breast tumor growth and progression in a transgenic breast cancer model, or tumor initiation and lung metastasis in patient-derived and human breast cancer xenografts, respectively9,10. Here, RPL39 is linked to breast carcinoma.